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Abstract 
Amylin is the 37-residue peptide hormone produced by the islet β-cells in the pancreas and the 
formation of amylin aggregates is strongly associated with β-cells degeneration in type 2 diabetes, as 
demonstrated by more than 95% of patients exhibiting amylin amyloid upon autopsy. 
It is widely recognized that metal ions such as copper(II) have been implicated in the aggregation 
process of amyloidogenic peptides such as Aβ and α-synuclein and there is evidence that also amylin 
self-assembly is largely affected by copper(II). For this reason, in this work, the role of copper(II) in 
the aggregation of amylin has been investigated by several different experimental approaches. Mass 
spectrometric investigations show that copper(II) induces significant changes in the amylin structure 
which decrease the protein fibrillogenesis as observed by ThT measurements. Accordingly, solid-state 
NMR experiments together with computational analysis carried out on a model amylin fragment 
confirmed the non fibrillogenic nature of the copper(II) induced aggregated structure. Finally, the 
presence of copper(II) is also shown to have a major influence on amylin proneness to be degraded by 
proteases and cytotoxicity studies on different cell cultures are reported. 
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Introduction 
Conformational disease is a general term often used to identify a number of disorders which are 
characterized by aggregation and deposition of specific proteins. Although the physiological roles of 
some of these aggregation-prone proteins have yet to be fully elucidated,1 it is possible to distinguish 
several different pathologies depending on the aggregation of a specific protein, i.e. β-amyloid for 
Alzheimer’s Disease,2 α-synuclein for Parkinson’s Disease, etc. In these diseases, the proteins in 
question are known to convert from their native functional state into highly organized fibrillar 
aggregates. In the case of amylin,3,4 the observation of amyloid deposits in islets of Langerhans of 
individuals with type 2 diabetes was for long time considered not important, probably because while 
researchers studying other pathologies were looking for protein to blame that could be responsible for 
the possible pathogenic mechanism, the research field of type 2 diabetes was already well established 
and mainly directed towards the study of insulin resistance.5 Many researchers regarded the observed 
failure of beta-cells only as a secondary event due to some elusive mechanism of “glucose toxicity”. In 
addition, it is important to note that amylin in mice or rats have a different amino acid sequence which 
confer to the amylin molecules different aggregation properties.6 Therefore, the use of these animals as 
models hindered the recognition of the connection between amylin aggregation and the pathology. 
In recent years, it has been documented that aggregates of amylin are directly toxic to beta-cells7 and 
much effort has been put toward the investigation of the possible factors triggering such aggregation.8-
10 Indeed, a common feature of all amyloid deposits is the association in situ with a number of 
cofactors such as membrane lipids, other proteins, glycosaminoglycans and metals.11 In the case of 
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amylin, many modulators of its aggregating properties have been identified.12-21 In this scenario, the 
role that some metal ions have in the aggregation of human22-24 or rat25 amylin and its fragments has 
also been investigated in recent years. While zinc(II) ions have been shown to inhibit the formation of 
aggregated and toxic forms of human amylin,22 providing a possible mechanism between the zinc 
transporter ZnT8 and type II diabetes,26 the role of copper(II) ions in the aggregation and 
dyshomeostasis of amylin has been controversial.27 Indeed, while previous studies correlated copper(II) 
ability to inhibit amylin fibrillation with toxicity,23,28 others pointed out that copper(II) may contribute 
to cytotoxicity by inducing amylin to form oligomers, which may contribute more to cell death than 
fibrils do.24 Mass spectrometry has also been applied to elucidate the structure of copper(II)-amylin 
complexes and the putative binding sites.29,30 However, there is a lack of study regarding the structure 
of copper(II)-induced amylin aggregates which could provide useful information for developing 
therapeutic strategies that could inhibit metal-induced aggregation and maybe even reverse it. Indeed, 
amylin homeostasis seems to be regulated also by the action of some metalloproteases which have been 
found to be able to degrade this hormone.31-33 The further role that copper(II) might have in modulating 
the degradation of amylin by these enzymes has not been studied, even if this metal ion has been 
proven to be able to tune the enzymatic activity of some of these metalloproteases.34-36The copper(II)-
driven conformational changes on h-amylin ought to have a large impact on its in vivo homeostasis. 
Particularly, as a major contribution to amylin catabolism in vivo seems to be given by its degradation 
by metalloproteases,31-33we have also studied the effect of copper(II) on amylin degradation by IDE. 
The latter seems to be involved in the proteolytic processing of many other different substrates,37,38 
which often also function as modulators of its activity39,40 and degradation of amylin by IDE has 
already been reported in the literature.41,42 However, the cleavage sites of IDE on amylin seem to 
depend on the particular conditions used, as different peptide fragments are reported in different 
published works.41,42 In this scenario, considering also the link that might exist between copper(II) 
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dyshomeostasis and type II diabetes,43 we have investigated the role of copper(II) ions into the packing 
and aggregating processes of human amylin (h-amylin) by several different experimental approaches. 
Particularly, information on the kinetics, the structure and the proneness of amylin aggregates to be 
degraded by metalloproteases have been obtained and discussed. Moreover, owing to the observation 
that amylin receptors, being shared between amylin and beta-amyloid peptides, appear to be also 
involved in the pathophysiology of Alzheimer’s disease44 and thus representing a molecular link 
between the two epidemiologically associated conditions, we have also measured the effect of copper 
on the toxic activity of h-amylin and its short peptide 17-29 on neuronal cell cultures. 
 
Experimental 
 
Materials and methods 
Insulin-degrading enzyme (IDE), His-Tag, rat, recombinant, Spodoptera frugiperda was purchased 
from CALBIOCHEM. Subtilysin, Elastase, Chymotrypsin and D2O were purchase from Sigma, while 
ZipTipC18 pipette tips were from Millipore (Billerica, MA, USA). h-amylin was purchased from 
BACHEM, while the 17-29 h-amylin fragment were synthesized as reported in ref. 10. For solid-state 
NMR measurements labelled 17-29 h-amylin fragments were synthesized: 1) Ser29-labelled with 13C3 
and 15N: [Rt = 20.30 min]. Mass calculated for: 12C56 13C3 H92 14N17 15N O20 = 1376.5 ; ESI-MS 
[Obsd m/z: (M+H)+ 1377.8] hIAPP17-29; 2) Val17-labelled with 13C5 and 15N: [Rt = 21.40 min]. 
Mass calculated for: 12C54 13C5 H92 14N17 15N O20 = 1378.5; ESI-MS [Obsd m/z: (M+H)+ 
1379.7]. The solvent gradients needed for labelled peptides purification were the same used for non-
labelled 17-29 h-amylin fragment and are reported in ref. 10. 
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Simulations 
Constant Temperature Molecular Dynamics (CTMD) simulations of the self-assembling of the N-
acetylated and C-amydated 17-29 h-amylin fragment were performed by using the software 
CHARMM33.  The peptide system was modelled by explicitly considering all heavy atoms and the 
polar hydrogen atoms bound to nitrogen and oxygen. The CHARMM 19 potential function was 
adopted and default cut-offs for long range interactions were used, i.e. a shift function of 1 Å was 
employed with a cut-off at 7.5 Å for both the electrostatic and van der Waals terms. Langevin 
dynamics with a friction value of 0.15 ps-1 were used. This friction coefficient is much smaller than the 
one of water (43 ps-1 at 330 K computed as 3π η d/m, where η is the viscosity of water at 330 K, and d 
and m are the effective diameter, i.e., 2.8 Å, and mass of a water molecule, respectively) to allow for 
sufficient sampling within the time scale (ns) of the simulations. It has been demonstrated that the 
small value of friction coefficient adopted does not influence the thermodynamic properties of the 
system, thus ruling out the possibility of kinetic traps along the aggregation pathway. The implicit 
solvent model EEF1 was employed to simulate the aqueous solvent. The SHAKE algorithm was used 
to fix the length of the covalent bonds involving hydrogen atoms; this option allows reducing the 
integration time step down to a value of 2 fs without affecting the reliability of the simulations. 
Furthermore, the non-bonded interactions were updated every ten dynamics steps and the coordinate 
frames were saved every 20 ps. A 20 ns implicit water MD simulation was performed on each single 
peptide at T=300 K to equilibrate the monomer. Ten replicas of the equilibrated monomer were then 
used to simulate aggregation in water. In the initial positions there were neither inter- or intra-
molecular contacts, i.e. the ten peptides were completely unfolded and not interacting in space. All 
simulations were started from random positions, orientations and conformation of the peptide copies. 
The final assembly was simulated in a cubic box of 600 Å side and re-equilibrated for 20 ns at 300 K.  
These conditions correspond to a final peptide concentration of 10µM. Additional MD runs carried out 
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by varying the size of the solvent box (i.e. at different peptide concentrations) did not modify the 
outcome of the simulations. Next, productive MD simulations were carried out at 300K for total 1µs.  
The polar order parameter  was considered to monitor the aggregation process as described elsewhere. 
The parameter P1, which is widely used to study the properties of anisotropic fluids, is defined as:  
 
   
 
where (the director) is a unit vector defining the preferred direction of alignment,   is the molecular unit 
vectors linking the peptide’s N- and C- termini and N is the number of molecules in the simulation box, 
i.e. three in the present study. The polar P1 describes how the molecular vectors point in the same 
direction, and discriminates between parallel and antiparallel/mixed ordered aggregates.  
The Root Mean Square Deviation (RMSD) analysis of an aggregate is usually employed to check the 
stability of the simulated system. The RMSD between two structures (corresponding to times ti and 
ti+1 of the trajectory) is defined as follows:  
 
 
 
where ri and ri+1 represent the position vectors of the N protein atoms calculated at time i and i+1 
respectively.  
 
Solid-State NMR 
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13C CPMAS NMR spectra were recorded at room temperature on a Varian Infinity plus spectrometer 
at a Larmor frequency of 75.47 MHz using a 3.2 mm MAS probe spinning at 25 kHz. TPPM 
decoupling at a field of 100 kHz was applied during acquisition of the 13C spectrum. Chemical shifts 
are quoted relative to TMS, using adamantane as a secondary external reference. 
 
Mass Spectrometry 
The peptide fragments generated by the enzymatic digestion of amylin by IDE were analyzed by using 
a Finnigan LCQ DECA XP PLUS ion trap spectrometer operating in the positive ion mode and 
equipped with an orthogonal ESI source (Thermo Electron Corporation, USA). Sample solutions were 
purified by ZIPTIPC18 and after dilution with 50 µl of water and 50 µl of Methanol were injected into 
the ion source at a flow-rate of 5 µl/min, using nitrogen as drying gas. The mass spectrometer operated 
with a capillary voltage of 46 V and capillary temperature of 250oC, while the spray voltage was 4.3 
kV. 
 
Hydrogen/ Deuterium exchange experiments 
The H/D exchange experiments were performed on h-amylin before and after incubation with copper 
(II) using a protein: metal molar ratios of 1:10. The latter condition was applied in order to ensure that 
the amount of free amylin in solution was negligible. Indeed, in figure 1S of the Supplementary 
Material the mass spectra and the peak assignment of three amylin-copper solutions at various molar 
ratios are reported. It can be noted that the 1:10 molar ratio ensures the maximum amount of amylin-
copper complex (the peak assigned to free amylin is absent in this case) without the formation of other 
species other than the 1:1 metal-amylin complex. For this reason this molar ratio was chosen for the 
H/D exchange and the limited proteolysis (see below) experiments. The H/D exchange was carried out 
as follows: the protein sample (600 pmol/µl) was equilibrated for 15 min at 25°C in ammonium acetate 
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10 mM pH 7. Deuterium exchange was initiated by 10-fold diluting the sample with ammonium acetate 
10mM, previously prepared using D2O at the appropriate pD. At various exchange times (from 15 sec 
to 1h), aliquots of 1.5 nmol of protein were withdrawn and rapidly analysed by LC/MS by direct 
injection into a HPLC coupled to a ZQ single quadrupole instrument (Waters), using a 30 x 0.46 mm 
reverse phase perfusion column (POROS 10 R1, Applied Biosystems). The protein was eluted at a flow 
rate of 0.5 ml/min with a 30-95% CH3CN gradient in 0.1% TFA in 1 min.  
The HPLC analysis was quickly performed with cold solvents keeping the column in an ice-bath to 
reduce the H/D back-exchange kinetics. In these conditions, deuterium ions from the amino acid side 
chains and the peptide C-terminus are rapidly substituted with hydrogens while exchange from amide 
bonds is much slower and can be measured. Duplicate analyses were performed for each time point.  
 
Limited Proteolysis Experiments 
The limited proteolysis experiments were performed on h-amylin before and after incubation with 
copper (II) using a protein: metal molar ratio of 1:10. Protein samples were individually treated with 
chymotrypsin, subtilisin and elastase. Enzymatic digestions were all performed in 50 mM ammonium 
hydrogen carbonate pH 7 at 25°C by using an E:S ratio (w/w) of 1:100 in the case of chymotrypsin and 
1:50 in the case of subtilisin and elastase. After 2h incubation, digestion was stopped by adding 
trifluoroacetic acid and aliquots of the peptide mixtures were directly analysed by MALDIMS. 
MALDI-MS analyses were carried out on a Voyager DE-PRO MALDI TOF (ABI Sciex) mass 
spectrometer equipped with a reflectron analyzer and used in delayed extraction mode with Voyager 
control software. 1µl of peptide mixture was mixed with an equal volume of a-cyano-4-
hydroxycynnamic acid as matrix (10 mg/ml in 0.2% TFA in 70% acetonitrile), loaded onto the metallic 
sample plate and air dried. Mass calibration was performed using the internal standard calibrants added 
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to the matrix. MALDI-MS data were acquired over a mass range of 250–6000 m/z in the positive mode 
using the software provided by the manufacturer. 
 
Sample preparation 
All peptide samples were subjected to a disaggregating procedure to remove any existing pre-
aggregated form before carrying out each experiment. The protocol consists in dissolving samples in 
1,1,1,3,3,3-hexa-fluoro-2-propanol (HFIP) at a concentration of 1mg/1ml and incubating them at 37°C 
for 1h. HFIP is then removed by gentle streaming with argon and the resulting peptide film dissolved 
again in 1 ml HFIP, frozen at -30 °C for 4-5 hours and lyophilized overnight. The lyophilized samples 
were then solubilized in MilliQ water to a concentration of 2x10-5 M adjusting the pH value just before 
the CD or ThT measurements. 
 
Circular Dichroism spectroscopy 
The Circular Dichroism (CD)  spectra were obtained at 37 °C under a constant flow of N2 on a Jasco J-
810 spectropolarimeter equipped with a Peltier thermoelectric type temperature control system. 
Experimental measurements were conducted at pH 7 using 1 cm or 0.1 cm path length cuvettes. The 
CD spectra were recorded in the UV region (190-260 nm) at peptide concentration of 2x10-5 M in 
MilliQ water. The CD spectra were acquired every 20 min over an experimental time course of 1500 
min. CD intensities are expressed as mean residue ellipticity [θ](deg cm2 dmol-1). 
 
Thioflavin-T assay 
Fluorescence emission spectra of Thioflavin-T (ThT) undergo a red shift upon incorporation into β-
sheet amyloid structures. Fluorescence was monitored as a function of time in a 96-well plate using a 
VARIOSKAN plate reader.  The measurements were carried out using, as a control, the time 
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dependence of the fluorescence of ThT solutions without the peptide. Samples were monitored over a 
1400 min period at an excitation wavelength of 450 nm and the emission was 480 nm. 
 
Cell cultures and h-amylin cytotoxicity 
Human neuroblastoma cell line (SH-SY5Y: ATCC® CRL-2266™) and insulinoma cell line (RIN-m: 
ATCC® CRL-2057™) were cultured in DMEM/F12 medium (1:1) and RPMI 1640 respectively, 
supplemented with 10% (v/v) fetal bovine serum (FBS), penicillin (50 U/ml) and streptomycin (50 
µg/ml). The cells were maintained in a humidified environment at 37°C and 5% CO2 and cultured in 75 
cm2 culture flasks. The medium was replaced twice a week and cells were splitted upon reaching about 
80% confluence. The day prior to treatment cells were harvested and seeded in 48-well plates at a 
density of 25000 cells/well. The cells were treated as soon as they reached maximal confluence.  
To evaluate the cytotoxicity produced by the h-amylin peptide, insulinoma and neuroblastoma cell 
cultures were treated for 48 hours with different preparations of 17-29 h-amylin peptide and full length 
protein, and viability was then measured by the classic MTT protocol. 
 
MTT ASSAY 
The toxicity of the peptides was measured through the determination of cell viability of treated cells 
compared to control (untreated cells), by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] assay. The test is based on the ability of the mitochondrial enzyme, cytochrome c oxidase and 
succinate dehydrogenase, to reduce yellow tetrazole into purple formazan that, being unable to cross 
the plasma membrane, will accumulate within the living cells. Solubilization of formazan crystals with 
an appropriate detergent will produce a purple solution, and absorbance measureswill indicate cells 
viability. After treatment with the peptide preparations, cell cultures were incubated for 1 hour at 37°C 
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in the MTT solution (1mg/ml in PBS); the formed crystals were melted with DMSO. After 
solubilization of the formazan crystals a microplate reader was used to read the absorbance at 590nm. 
 
Results and discussion 
To study the conformational changes that copper(II) ions could induce on h-amylin, solutions of the 
latter (20  µM) were diluted 10-fold by the addition of the appropriate D2O amount and deuterium 
incorporation was monitored by sampling the incubation mixture at different interval times followed by 
cold acid quenching and fast LC/MS analysis. Since H/D exchange of amide deuterons occurs very 
slowly, the increase in molecular mass of the protein sample constituted a direct measurement of 
deuterium incorporation at peptide amide linkages. The number of amide protons exchanged with 
deuterium in the native form of h-amylin and h-amylin-Cu (II) complex as a function of time is 
reported in Figure 1. Native h-amylin showed two distributions of multiply charged ions in the ES mass 
spectra, eventually originating two curves, thus suggesting the occurrence of two different 
conformations of the protein having a clear difference in the exchange kinetics. Following 60 min of 
reaction, the two protein conformations exchanged a total of 25 and 5 hydrogens respectively, thus 
indicating the existence of an equilibrium between a higher unstructured conformation and a more 
compact structure. The analysis of the relative abundances of the two conformers as estimated by mass 
peak intensities showed that h-amylin in solution essentially adopts an unstructured conformation with 
a minor fraction of molecules assuming a more compact structure. Following Cu-complex formation, 
we observed the occurrence of a single compact conformation of h-amylin that exchanged very few 
protons. This behaviour almost resembled that of the most stable conformation observed in the analysis 
of the isolated protein. A possible interpretation of the data suggests that in solution h-amylin gives rise 
to an equilibrium between two conformations, with the more unstructured state being the most 
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populated. The presence of copper(II) greatly shifted the equilibrium towards the more compact 
structure that eventually constitutes the only existing conformer. 
A further confirmation of the copper(II)-induced change in the conformation was obtained by carrying 
out limited proteolysis experiments using an array of different enzymes including Subtilysin, Elastase 
and Chymotrypsin in enzyme/substrate ratios of 1/50 for Subtilysin and Elastase or 1/100 in the case of 
Chymotrypsin (see Figure 2S of the supplementary material). Limited proteolysis was carried out at 
37°C in 50 mM of ammonium hydrogen carbonate hydrolysis buffer at pH 7 for 2h. The MALDI-MS 
analyses allowed to monitor the changes in the cleavage sites after copper(II) addition (see Figure 2). It 
was so possible to establish that the copper(II) binding site is located in the region containing the His18 
residue which is likely the metal binding site. This result was further confirmed by using IDE as amylin 
proteolytic enzyme (see introduction). Figure 3 shows that, in the presence of copper(II), the cleavage 
sites of IDE on amylin (determined by the MS detection of the IDE-produced amylin fragments, data 
not shown) decreased in number but also, more importantly, changed drastically. It was particularly 
interesting that, apart from the expected inhibitory role of copper(II) on amylin degradation by IDE 
(data not shown),34,36,45 the enzyme was no longer able to cut the peptide in the middle part of its 
sequence, indicating that conformational changes driven by copper(II) binding to this segment of 
peptide chain renders the latter unavailable for enzymatic hydrolysis. 
Once it was assessed that copper(II) induces a conformational change on the h-amylin molecules, we 
decided to investigate the aggregation kinetics of h-amylin in the presence and in the absence of the 
metal ion. For this purpose, CD as well as ThT fluorescence measurements were carried out on the 
various samples. In Figure 4 the CD spectra of h-amylin incubated at 37oC with copper (II) at different 
times are reported together with the CD profile of the protein alone. In the absence of copper the 
polypeptide adopts a random coil conformation, while in the presence of metal ions h-amylin 
conformation shifts toward a mix of random coil and α-helix structures. Indeed, the minimum near 200 
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nm undergoes a red shift over time which indicates a stabilization of an α-helix conformation, while 
there is not the presence of the negative peak at 216 nm over time, confirming the absence of β-sheet 
structures.46 Therefore, although copper induces a conformational change onto the h-amylin molecule 
which shifts the equilibrium toward a more structured form (see MS results), the lack of β-sheet 
structures as seen by CD indicates the absence of an induced fibrillar form of the protein. This result 
was further confirmed by ThT fluorescence measurements. Figure 5 shows the h-amylin ThT kinetics, 
recorded at pH 7.0 in the absence and in the presence of copper(II) (1:1 ratio). In the absence of 
copper(II) a short lag phase (near 100 min.) followed by a rapid growth of ThT fluorescence was 
observed. In contrast, in the presence of copper the lag phase was almost 3 times longer and the 
fluorescence intensity after 600 minutes was more than 2 times lower, confirming the absence of metal 
induced fibrillar form of h-amylin. Indeed, copper(II) induces a conformational change on the protein 
that, although is in a more structured state (H/D exchange MS and CD results), is less prone to 
aggregation, in accordance with previous works.23,46 
Finally, in order to get a closer insight onto the mechanism by which copper(II) induces the above 
reported changes on both the conformation and aggregation properties of h-amylin, we have used the 
17-29 h-amylin fragment (Figure 3) in order to carry out simulations as well as solid-state NMR 
measurements on the aggregated state. The reason and the validity of using this particular peptide 
portion has already been reported elsewhere.10 Figure 6 shows 13C CPMAS spectra of three 17-29 h-
amylin fragments (A-C). Sample A is the native 17-29 h-amylin fragment, with U-13C3-15N1-Ser29 
isotopic labelling. Sample B is the same fragment, which has been bound to copper(II) ions in a 1:1 
ratio. Sample C is 17-29 h-amylin fragment with U-13C5-15N1 Val17 which has also been bound to 
copper(II) ions in a 1:1 ratio. Observed shifts are recorded in ppm (see Table 1), spectra were recorded 
at 25 kHz. All spectra displayed a broad peak arising from natural abundance 13C nuclei which are 
present in all residues. Sample A showed three sharp resonances for the carbonyl, α and β carbons of 
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the universally labelled Ser29 residue consistent with the values reported in the literature for full length 
h-amylin.47 Sample B clearly displayed shift differences compared to A, consistent with a hyperfine 
coupling to the paramagnetic copper(II) ions present. Only two resonances were observed, which were 
attributed to the α and β carbons. This suggests that the carbonyl signal has been broadened due to 
paramagnetic relaxation effects. Sample C also displayed large differences form the expected shifts due 
to paramagnetic couplings. These data indicate that both Val17 and Ser29 residues at each end of the 
fragment experience significant paramagnetic shifts and are therefore both close in space to the 
copper(II) ion. 
Far-Uv CD spectroscopy was used also to monitor the h-amylin 17-29 peptide conformational changes 
associated with fibril formation. Aggregation kinetics monitored by CD spectroscopy were measured in 
the presence of copper(II) at pH 7 in water as above described, showing that copper(II) modifies the 
polypeptide conformation. The CD profile shown in Figure 7 appears to be a mixture between random 
coil and folded structure. The spectra recorded without metal showed a typical random coil 
conformation but after copper(II) addition, the 222 nm ellipticity increased while the 200 nm ellipticity 
was reduced. It is important to note that the CD spectra relevant to h-amylin 1-37 and the shorter 
peptide h-amylin 17-29 appear quite different. The analysis of the CD profiles suggests that copper(II) 
coordination brings structuring effects into the polypeptide backbone. This should occur particularly in 
the peptide region involved in metal ion binding where the coordinated amino acid residues induce the 
adoption of a peptide bent conformation that is mainly driven by the geometrical coordination 
preferences of the metal ion and by the stability of the formed chelate rings. This new locally defined 
conformation contributes with a distinctive dichroism to the observed spectral pattern. Such an effect 
becomes more evident in the CD curves of the shorter h-amylin 17-29 peptide sequence. The difference 
spectra obtained by subtracting the CD traces recorded without metal from those obtained in the 
presence of copper(II), should, in principle, give an indication of the difference of backbone 
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conformation caused by copper(II) complexation. Indeed, what we observe is that the resultant CD 
curves give strikingly similar CD profiles with a positive ellipticity below 200 nm and a negative signal 
centred around 217-220 nm (see Figure 3S of the supplementary material). This in our opinion strongly 
suggests, that in both cases, copper(II) experiences a similar coordination environment and this can 
justify the use of the shorter peptide fragment to study the metal binding site of the full-length protein. 
Finally, CTMD simulations performed at T= 300K in implicit water have shown that the ten replicas of 
the 17-29 h-amylin fragment exhibited low values of both RMSD and its fluctuations (Figure 8) thus 
suggesting that they rapidly collapse to give a stable, compact structure.  
An analysis of the secondary structure percentages averaged along the entire simulation provided 
information about the conformational preferences of the peptide in the condensed state (Table 2) that 
was found in agreement with the solid-state NMR results. Indeed, the purpose of MD simulations is to 
support an head-to-tail topological arrangement of 17-29 h-amylin aggregates. This information is 
important to support the interpretation of the solid-state NMR experiments. Actually, Val17 and Ser29 
residues at each end of the 17-29 h-amylin fragment experience significant paramagnetic shifts and are 
therefore both close in space to the copper(II) ion. However, the C-terminus of 17-29 h-amylin is not 
supposed to bind copper(II) and, as a consequence, the NMR results may be explained i) assuming that 
copper(II) binds the N-terminus (Val17) of the peptide and induce the molecule to bend and adopt a U-
shaped structure or ii) supposing an head-to-tail arrangement of the peptide aggregates. In general, little 
is known about the metal-binding sites in the aggregated state of peptides and it is difficult to establish 
by experiments which of these two hypotheses holds true when the peptide aggregates. Therefore, we 
resorted to CTMD simulations which pointed clearly to an head-to-tail topological arrangement of the 
aggregated peptides. All these simulations were performed in the absence of copper(II) ions. We are 
aware that MD simulations performed in the presence of copper ions would allow a better comparison 
with NMR results. However, the presence of a metal ion in the system would make the use of QM 
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simulations much safer, as they embody charge polarization and screening, rather than the use of the 
purely classical MD adopted in the present work. But an obvious limitation to the use of QM 
simulations is the foreseeable very short length of the computed trajectory (few picoseconds for 
systems of the size one is interested in here by using commonly-available hardware resources) which 
certainly cannot fully account for the complicated peptide aggregation dynamics. 
The time evolution of the secondary structure for each replica of the 17-29 h-amylin fragment, reported 
in Figure 9, underlines the high tendency to self-assembly in beta-sheet for this system. This 
observation is consistent with the RMSD curves of the 17-29 h-amylin fragment in water that are 
typical of a structured system with high rigidity and compact packing. Figure 10 shows a representative 
snapshots of the 17-29 h-amylin fragment aggregated in water. In principle, in the early steps of 
aggregation, all amyloidogenic peptides assembled into highly ordered β-sheet structures. During the 
assembly, the peptides tend to align adopting an extended β-strand conformation and a remarkable 
change in the local orientational order occurs. The aggregation of amyloid forming peptides may then 
be interpreted as an order transition and orientational order parameters are suitable to monitor the time 
evolution of the process. Figure 11 reports the projections along the polar order parameter P1 of the 17-
29 h-amylin fragment assemblies calculated as reported in the experimental section. The CTMD 
profiles along P1 show that at room temperature T = 300K macrostates arranged in an anti-parallel β-
sheet configuration are highly populated (0<P1<0.3). To a lower extent, mixed parallel/antiparallel 
arrangements are populated (0.3<P1<0.7). At higher P1 values (P1>0.7) where only parallel 
arrangements are supposed to exist, the CTMD profiles are close to zero suggesting that parallel 
arrangements are not likely to be present during the simulations.  
All the observed conformational changes induced by incubation of peptide alone or in the presence of 
Cu(II), should affect not only the status of aggregation, but also its toxic property. We therefore 
evaluated the relationship between aggregating conditions and toxicity on insulinoma cell line culture 
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and, in order to provide further proofs on the correlations between diabetes and Alzheimer’s disease, 
we also used the neuronal cell line, SH-SY5Y, as cell culture model. Cells at full confluence were 
treated for 48 hours with 17-29 h-amylin preparations (25µM), that consist in pre-incubation in vitro 
alone or in the presence of CuSO4 (at 1:1 molar ratio) for 48 hours in PBS 0,01M, pH 7,4. The data 
obtained showed a reduced viability (decreased ability to reduce MTT), compared to control (Fig. 12), 
in all the samples treated with 17-29 h-amylin. It cannot be excluded any further changes in the status 
of aggregation during the 48hs of cell culture treatment. This could explain the toxicity exerted by the 
freshly prepared (not pre-incubated) peptide (-20%). The peptide pre-incubation alone or in the 
presence of CuSO4 (at 1:1 molar ratio) further increases its toxicity (-40% and -50% of viability 
respectively). The stronger decrease in cell viability observed after treatment with the peptide/Cu(II) is 
in accordance with the ability of copper to counteract β-sheet conformational changes and 
fibrillogenesis, thus prolonging the presence of more toxic and self-assembling oligomeric species. 
However it cannot be excluded that cell viability could also be affected by the formation of toxic free 
radical species produced in the presence of Cu(II). The treatment of neuroblastoma as well as 
insulinoma cell cultures with h-amylin 1-37 (full protein) preparations (20µM) for 48 hours, revealed 
that amylin toxic effect was, in this case, not affected by the presence of copper ions during the 48h of 
in vitro pre-incubation (Figures 13 and 14). This result could be related and is in agreement with the 
measured differences of CD spectra and the absence of metal induced β-sheet structures (fibrillar form) 
of h-amylin. 
 
Conclusions  
Several different experimental techniques as well as CTMD simulations have been applied in order to 
assess the conformation of h-amylin in the presence and in the absence of copper(II). The latter metal 
ion has been shown to drastically affect both the fibers structure and aggregation kinetics of h-amylin, 
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as well as its proneness to be degraded by proteases. Particularly, MS data indicate that h-amylin gives 
rise to an equilibrium between two conformations, with the more flexible state being the most 
populated, while CD spectra of h-amylin are in accordance with a random coil conformation and 
incubation of the peptide alone leads to aggregation. The presence of copper(II) induces the formation 
of a more compact structure that eventually constitutes the only existing conformer. However, no clear 
signs of β-sheet conformation could be observed from the spectroscopic patterns recorded in  the 
presence of copper(II), thereby suggesting that the metal ion can inhibit h-amylin fibril formation. The 
copper(II)-h-amylin species are less prone to enzyme and metalloproteases degradation, revealing that 
the metal binding has to occur within the 17-29 h-amylin region and the coordination features of this 
peptide fragment are in progress. Solid-state NMR as well as CTMD simulations indicated the presence 
of mixed parallel/antiparallel arrangements, confirming the randomness of this specific metal ion-
induced aggregation process.  
These conformational changes can also explain the highest level of toxicity that we observed after cell 
culture treatment with 17-29 h-amylin fragment preincubated in the presence of Cu(II) and the absence 
of effects of copper on h-amylin 1-37 spontaneous evolution towards toxic species. 
Finally, we believe that, as copper(II) dyshomeostasis seems to be involved in the development of type 
II diabetes, the reported differences observed both in the kinetics as well as in the kind of the 
aggregates of h-amylin in the presence and in the absence of copper(II) may have important 
implications in vivo which should be further investigated. 
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Tables 
 
Literature	   h-­‐amylin	  /	  ppm	  
Val17	   171.7	  
58.8	  
34.2	  
19.6	  
Ser29	   171.9	  
64.8	  
54.9	  
Sample	   17-­‐29	  h-­‐amylin	  
fragment	  copper(II)	  /	  
ppm	  
C:	  Val17	   125	  
85	  
20	  
B:	  Ser29	   175	  
85	  
	   17-­‐29	  h-­‐amylin	  
fragment/	  ppm	  
A:	  Ser29	   175	  
60	  
50	  
 
Table1. Chemical shifts observed for 17-29 h-amylin fragments A-C. Top: reported shifts of Val17 and 
Ser29 in the full-length h-amylin. Bottom: observed shifts for 17-29 h-amylin fragments A-C. 
 
 
helix sheet coil turn 
0.04 27.72 38.08 34.14 
 
Table 2. Secondary structure averaged along simulation in water. 
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Figure Legends 
 
Figure 1: Number of amide protons exchanged with deuterium in the native form of h-amylin and h-
amylin-Cu (II) complex as a function of time. H-amylin showed two distributions of multiply charged 
ions in the ES mass spectra, eventually originating two curves indicated 1A and 1B. Discussion is in 
the text. 
 
Figure 2. Main limited proteolytic sites in h-amylin (black blocks) and the Cu(II)-h-amylin complex 
(grey blocks). Chymotrypsin digestion sites: F15, L16, F23 and L27; Elastase digestion sites: A13, 
S20, L27 and V32; Subtylisin digestion sites: L12, L16, L27, G33 and N35. 
 
Figure 3: Cleavage sites of IDE on h-amylin as reported in ref. 41 (black solid arrows), as reported in 
ref. 42 (grey solid arrows), as obtained in this work after 2h at 37oC of h-amylin solution (50 µM in 
PBS), IDE 0.2 µM, without (black dashed arrows) and with (grey dashed arrows) copper(II). Grey 
amino acidic residues refer to the amylin portion used as a model for solid-state NMR and 
computational studies. 
 
Figure 4: CD spectra of h-amylin 2*10-5 M in water recorded at different times of incubation at 37oC 
with equimolar copper (II). The dotted curve refers to the CD profile in the absence of the metal ion at 
the same experimental conditions. 
 
Figure 5: Kinetics of fibril formation monitored by ThT fluorescence of h-amylin (2*10-5 M) in water 
solution at pH = 7 and 37oC without (solid line) and with (dotted line) copper(II) (2*10-5 M).  
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Figure 6: 13C CPMAS spectra of the 17-29 h-amylin fragments. C: prepared using U-13C5-15N1 
Val17 and Cu(II), B: prepared using U-13C3-15N1 Ser29 and Cu(II), A: prepared using U-13C3-15N1 
Ser29 only. 
 
Figure 7: CD spectra of 17-29 h-amylin fragment (2*10-5 M) recorded at different time intervals (from 
0 to 21 h) at pH 7.0 and at 37oC in water solution in the presence of equimolar copper(II).The dotted 
curve refers to the CD profile in the absence of the metal ion at the same experimental conditions. 
 
Figure 8: RMSD of the ten-meric assembly of the 17-29 h-amylin fragment, in water. 
 
Figure 9: Time evolution of the secondary structure of the 17-29 h-amylin fragment during the early 
stages of aggregation (the first 4 ns) in water as obtained from the analysis of hydrogen bonds in the 
peptide main chain by the VMD software. Here, the vertical coordinate represents the residue number 
from the first to the 10th replica which is plotted against time. The secondary structure is color-coded. 
 
Figure 10: A snapshot of the ten-meric aggregate of the 17-29 h-amylin fragment in water. 
 
Figure 11: Percentage of populations of ten-meric 17-29 h-amylin fragment assemblies plotted along 
the polar P1, order parameter. Schematic representations of the aggregates (black arrows) are depicted 
to show that order parameter P1 discriminates between parallel and antiparallel/mixed ordered 
aggregates. 
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Figure 12: MTT assay after 48 hrs of treatment of SHSY5Y cell cultures with different 17-29 h-amylin 
preparations (25µM). Data are means ± S.D. (n=4) of 3 independent experiments, and expressed as 
percent vs. control. Statistical analysis was performed by one way ANOVA, all Pairwise Multiple 
Comparison Procedures (Holm-Sidak method): significant comparisons are indicated by horizontal 
curly brackets. 
 
Figure 13: MTT assay after 48 hrs of treatment of insulinoma (RIN-m) cell cultures with different 
h-amylin 17-29 preparations (25µM). Data are means ± S.D. (n=5) of 2 independent experiments, and 
expressed as percent vs. control. Statistical analysis was performed by one way ANOVA, all Pairwise 
Multiple Comparison Procedures (Holm-Sidak method): significant comparisons are indicated by 
horizontal curly brackets. 
 
Figure 14: MTT assay after 48 hrs of treatment of neuroblastoma (SHSY5Y) cell cultures with 
different h-amylin 1-37 preparations (20µM). Data are means ± S.D. (n=5) of 2 independent 
experiments, and expressed as percent vs. control. Statistical analysis was performed by one way 
ANOVA, all Pairwise Multiple Comparison Procedures (Holm-Sidak method): significant comparisons 
are indicated by horizontal curly brackets. 
 
Figure 15: MTT assay after 48 hrs of treatment of insulinoma cell cultures with different h-amylin 
1-37 preparations (20µM). Data are means ± S.D. (n=4) of 3 independent experiments, and expressed 
as percent vs. control. Statistical analysis was performed by one way ANOVA, all Pairwise Multiple 
Comparison Procedures (Holm-Sidak method): significant comparisons are indicated by horizontal 
curly brackets.
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